<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944110</url>
  </required_header>
  <id_info>
    <org_study_id>H-15009763</org_study_id>
    <nct_id>NCT02944110</nct_id>
  </id_info>
  <brief_title>Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism</brief_title>
  <acronym>PX-GRA</acronym>
  <official_title>Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes are characterised not only by compromised insulin secretion and&#xD;
      action, but also by elevated plasma levels of the 29-amino acid peptide hormone glucagon,&#xD;
      which hitherto has been considered a pancreas-derived hormone (produced in and secreted from&#xD;
      alpha cells in the islets of Langerhans). In patients with diabetes, circulating glucagon&#xD;
      concentrations are elevated in the fasting state and fail to decrease appropriately or even&#xD;
      increase in response to an oral glucose tolerance test (OGTT) or after ingestion of a mixed&#xD;
      meal. Hyperglucagonaemia is known to be a potent stimulator of hepatic glucose output, and,&#xD;
      thus, contributes significantly to the fasting and postprandial hyperglycaemia characterising&#xD;
      patients with diabetes. Despite intense research over the years the mechanisms behind the&#xD;
      elevated glucagon levels in diabetes is still not clear. Recently, the investigators showed&#xD;
      that totally pancreatectomised patients also show a hyperglucagonaemic response during OGTT,&#xD;
      a finding that suggests that the pancreas is not the only source of glucagon production in&#xD;
      man.&#xD;
&#xD;
      In the present project, the investigators wish to evaluate the impact of gastrointestinally&#xD;
      derived glucagon secretion observed in totally pancreatectomised patients on postprandial&#xD;
      glucose tolerance.&#xD;
&#xD;
      The investigators hypothesise that antagonisation of glucagon signalling (from&#xD;
      gastrointestinally derived glucagon) in totally pancreatectomised patients will improve or&#xD;
      perhaps normalise the patients glucose tolerance during a 75g-OGTT. In order to test this&#xD;
      hypothesis, the investigators wish to apply the potent and selective oral antagonist of the&#xD;
      human glucagon receptor LY2409021 and placebo, respectively.&#xD;
&#xD;
      The study is a randomised, placebo-controlled, double-blinded, cross-over study.&#xD;
&#xD;
      10 healthy persons and 10 pancreatectomized patients (i.e. patients who have had their&#xD;
      pancreata removed due to pancreatic cancer or severe chronic pancreatitis) will be subjected&#xD;
      to two experimental days with LY2409021 and placebo, respectively, on which they will undergo&#xD;
      an OGTT followed by a fasting period and finished off with an ad libitum meal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPG excursions measured as incremental area under curve (iAUC)</measure>
    <time_frame>-120,-45,-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences in gastric emptying, measurement of s-paracetamol</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
    <description>measurement of time to peak and incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food intake and appetite</measure>
    <time_frame>at time 0,30,60,90,120,150,180 minutes</time_frame>
    <description>assessed by a visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting energy expenditure (REE)</measure>
    <time_frame>-90,30,150 minutes</time_frame>
    <description>measured by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p-glucose mmol/L</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon pmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free fatty acids μmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p-triglyceride mmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino Acid concentration μmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
    <description>total and fractionated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholecystokinin pmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric inhibitory peptide (GIP) and Glucagon like peptide-1 (GLP-1) pmol/l</measure>
    <time_frame>-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes After Total Pancreatectomy</condition>
  <arm_group>
    <arm_group_label>Pancreatectomised + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatectomised + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy + LLY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon receptor antagonist LY2409021</intervention_name>
    <description>single oral dose of 300mg</description>
    <arm_group_label>Healthy + LLY2409021</arm_group_label>
    <arm_group_label>Pancreatectomised + LY2409021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose of placebo tablets</description>
    <arm_group_label>Healthy + placebo</arm_group_label>
    <arm_group_label>Pancreatectomised + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Pancreatectomised patients&#xD;
&#xD;
          -  Caucasian above 18 years of age who have undergone total pancreatectomy&#xD;
&#xD;
          -  Normal haemoglobin&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  Normal fasting plasma glucose and normal HbA1C (according to the World Health&#xD;
             Organization (WHO) criteria)&#xD;
&#xD;
          -  Normal haemoglobin&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Pancreatectomised patients&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Operation within the last 3 months&#xD;
&#xD;
          -  Ongoing chemotherapy or chemotherapy within the last 3 months&#xD;
&#xD;
          -  Gastrointestinal resection (other than the gastro-duodenectomy performed in connection&#xD;
             with total pancreatectomy) and/or ostomy&#xD;
&#xD;
          -  Nephropathy (serum creatinine &gt;150 µmol/l and/or albuminuria)&#xD;
&#xD;
          -  Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate&#xD;
             aminotransferase (ASAT) &gt;3× normal values)&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Age above 80 years&#xD;
&#xD;
          -  Uncontrolled hypertension and/or significant cardiovascular disease&#xD;
&#xD;
          -  Any condition that the investigator feels would interfere with trial participation&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  Diabetes or prediabetes (according to the WHO criteria)&#xD;
&#xD;
          -  First-degree relatives with diabetes&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Gastrointestinal resection and/or ostomy&#xD;
&#xD;
          -  Nephropathy (serum creatinine &gt;150 µM and/or albuminuria&#xD;
&#xD;
          -  Liver disease (ALAT and/or serum ASAT &gt;2×normal values)&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Age above 80 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of department at Center for Diabetes Research, Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

